Branded

Genentech’s Xofluza now is indicated to include post-exposure prevention of influenza for patients 12 years old and older after contact with a person with the flu.

Merck will acquire Oncolmmune, which recently announced positive findings from a Phase 3 study of its candidate for the treatment of patients with severe and critical COVID-19.

Eli Lilly and Incyte have received emergency use authorization from the Food and Drug Administration for baricitinib in combination with remdesivir in hospitalized adult and pediatric patients age 2 years old or older with COVID-19.

UCB’s Vimpat has received the Food and Drug Administration’s nod for primary generalized tonic-clonic seizures, as well as expanded pediatric use for people with epilepsy.

Eli Lilly's bamlanivimab has received the Food and Drug Administration’s nod for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients.

AstraZeneca’s Brilinta (ticagrelor) is now approved to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack.

Kala Pharmaceuticals' Eysuvis provides a short-term treatment of the signs and symptoms for dry eye disease.

Sanofi has agreed to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products.

Yew Looi Liew succeeds Jean-Michel Boers as president of Boehringer Ingelheim's U.S. human pharma.

Gilead Sciences' Veklury has been approved to treat hospitalized patients with COVID-19 who are 12 years old and older.

The DOJ's settlement agreement will pave the way for Purdue to submit a plan of reorganization to the bankruptcy court that will transfer all of Purdue’s assets to a public benefit company.

Regeneron’s Inmazeb is the first FDA-approved treatment for Ebola virus infection in adult and pediatric patients.